Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Study Evaluating Management of Patients With Moderate and Severe Psoriasis

This study has been completed.
Sponsor:
Information provided by:
Wyeth is now a wholly owned subsidiary of Pfizer
ClinicalTrials.gov Identifier:
NCT00894777
First received: May 6, 2009
Last updated: November 19, 2010
Last verified: November 2010
  Purpose

This is an observational, naturalistic, multicenter, retrospective study to describe the therapeutic management of patients with moderate and severe psoriasis under treatment with topical and/or systemic drugs in usual clinical practice in Spain.


Condition Intervention
Psoriasis
Other: Clinical record review

Study Type: Observational
Study Design: Observational Model: Case-Only
Time Perspective: Retrospective
Official Title: Management of Patients With Moderate and Severe Psoriasis Under Treatment With Topical and/or Systemic Drugs

Resource links provided by NLM:


Further study details as provided by Wyeth is now a wholly owned subsidiary of Pfizer:

Primary Outcome Measures:
  • Descriptive analysis of the therapeutic management of patients with moderate and severe psoriasis under treatment with topical and/or systemic drugs including sequence, doses and duration of treatment. [ Time Frame: 4 months ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Comparison of therapeutic management depending on patients' disease severity, using absolute and relative frequencies for qualitative variables and centralization and dispersion measures (mean, SD, median, minimum, maximum..) for quantitative variables. [ Time Frame: 4 months ] [ Designated as safety issue: No ]

Enrollment: 469
Study Start Date: March 2009
Study Completion Date: November 2009
Primary Completion Date: November 2009 (Final data collection date for primary outcome measure)
Groups/Cohorts Assigned Interventions
1
Patients with moderate and severe psoriasis under treatment with topical and/or systemic drugs
Other: Clinical record review

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population

Patients with moderate and severe psoriasis under treatment with topical and/or systemic drugs in usual clinical practice

Criteria

Main Inclusion Criteria:

·Over 18 years of age.·Diagnosed with moderate or severe psoriasis.·Initiated treatment with topical and/or systemic treatment between two and five years before enrollment in the study. ·Has a clinical record at the dermatologist office.

Main Exclusion Criteria:

·Currently participating in a clinical study. ·Clinical record lacks minimum data required for observational analysis.

  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00894777

Locations
Spain
Madrid, Spain, 28031
Sponsors and Collaborators
Wyeth is now a wholly owned subsidiary of Pfizer
Investigators
Study Director: Pfizer CT.gov Call Center Wyeth is now a wholly owned subsidiary of Pfizer
  More Information

No publications provided

Responsible Party: Director, Clinical Trial Disclosure Group, Wyeth
ClinicalTrials.gov Identifier: NCT00894777     History of Changes
Other Study ID Numbers: 0881A6-4577
Study First Received: May 6, 2009
Last Updated: November 19, 2010
Health Authority: Spain: Comité Ético de Investigación Clínica

Keywords provided by Wyeth is now a wholly owned subsidiary of Pfizer:
Psoriasis

Additional relevant MeSH terms:
Psoriasis
Skin Diseases
Skin Diseases, Papulosquamous

ClinicalTrials.gov processed this record on November 24, 2014